All In Biotech

Drug Trial Radar · NCT06730061

A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)

A Phase III, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Elafibranor 80 mg in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

18

Actual

Start

Jan 16, 2025

Primary completion

Dec 17, 2026

Study completion Apr 8, 2032

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Dec 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out about the safety and how well the study intervention (elafibranor) works in participants with PBC. The participants in this study will have confirmed PBC with inadequate response or intolerance to UDCA, which is a medication used in the management and treatment of cholestatic liver disease. PBC is a slowly progressive disease characterised by damage of the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many patients with PBC may require a liver transplant or may die if the disease progresses and a liver transplant is not done. In this study all participants will receive a daily dose of elafibranor (the study intervention). The main aim of this study is to determine if elafibranor reduces alkaline phosphatase (ALP) and total bilirubin levels. High ALP and bilirubin levels in the blood can indicate liver disease. There will be 4 periods in this study: A screening period (up to 10 weeks) to assess whether the participant can take part. A treatment period (52 weeks) where all eligible participants will receive elafibranor. A variable treatment extension period (2-5 years) from End Of Treatment (EOT) period up to the commercial availability of elafibranor in Japan. A follow-up period (4 weeks) where participants' health will be monitored. Participants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), ultrasound examinations (a non-invasive test that passes a probe over skin to look at the bladder, urinary tract, and liver), and Fibroscan® examinations (to measure stiffness of the liver). They will also be asked to fill in questionnaires. Each participant will be in this study for up to approximately 6 years

Conditions

  • Primary Biliary Cholangitis

Interventions

  • ElafibranorDrug

    Tablet of 80 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with Alkaline phosphatase (ALP) <1.67x ULN, ALP decrease ≥15% and Total Bilirubin (TB) ≤ ULNTime frame: At Week 52

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Nippon Medical School - Chiba Hokusoh Hospital

    Chiba, Japan

  • Fukushima Medical University Hospital

    Fukushima, Japan

  • Chugoku Rosai Hospital

    Hiroshima, Japan

  • Teine Keijinkai Hospital

    Hokkaido, Japan

  • Kagawa University Hospital

    Kagawa, Japan

  • Kagoshima University Hospital

    Kagoshima, Japan

  • Shinshu University Hospital

    Nagano, Japan

  • National Hospital Organization Nagasaki Medical Center

    Nagasaki, Japan

  • Nara Medical University Hospital

    Nara, Japan

  • Nagaoka Red Cross Hospital

    Niigata, Japan

  • Niigata University Medical & Dental Hospital

    Niigata, Japan

  • National Hospital Organization Osaka National Hospital

    Osaka, Japan

  • Hamamatsu University Hospital

    Shizuoka, Japan

  • Juntendo University Hospital

    Tokyo, Japan

  • Teikyo University Hospital

    Tokyo, Japan

  • Tokyo Metropolitan Komagome Hospital

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.